BD Kiestra
Advancing the world of health by improving medical discovery, diagnostics and the delivery of care.
Launch date
Market cap
CAD92.8b
Enterprise valuation
CAD111.9b (Public information from Sep 2024)
Share price
$231.59 BDX
Eysins Canton of Vaud (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 17.3b | 17.1b | 20.2b | 18.9b | 19.4b | 20.1b | 21.4b |
| % growth | 8 % | (1 %) | 18 % | (7 %) | 3 % | 4 % | 6 % |
| EBITDA | 4.1b | 4.0b | 5.2b | 4.6b | 4.7b | - | - |
| % EBITDA margin | 24 % | 23 % | 26 % | 24 % | 24 % | - | - |
| Profit | 1.2b | 874m | 2.1b | 1.8b | 1.5b | - | - |
| % profit margin | 7 % | 5 % | 10 % | 9 % | 8 % | - | - |
| R&D budget | 1.1b | 1.1b | 1.3b | 1.3b | 1.2b | - | - |
| R&D % of revenue | 6 % | 6 % | 7 % | 7 % | 6 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
€420k | Grant | ||
N/A | Acquisition | ||
| Total Funding | CAD630k | ||